Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | July 13, 2017 | July 13, 2017 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Exec Chairman of the Board | January 26, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
IONIS PHARMACEUTICALS INC
Report date January 26, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,021 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Sale · Disposed 28,333 · Balance 2,021 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 3,111 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,111 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 494,391 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 494,391 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 39,643 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,160 Underlying: Common Stock · 39,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,545 Underlying: Common Stock · 5,545 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_price: Grant to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 62,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,982 Underlying: Common Stock · 62,982 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 1,268 | $62.06 | $78,692.08 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 7,581 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 8,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 17,342 | $62.06 | $1,076,244.52 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,935 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 39,643 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 23:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,477 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-20-000008 · edgar.xml · derivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 12,477 Underlying: Common Stock · 12,477 shares Expires 2027-01-01 F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 23:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 141,709 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-20-000008 · edgar.xml · derivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,709 Underlying: Common Stock · 141,709 shares Expires 2027-01-01 F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| December 06, 2019 Filed Jan 3, 2020 23:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000004 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 700,391 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · derivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,180 Underlying: Common Stock · 10,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $72.15 | $721,500.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.10 to $72.20, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $39.87 | $398,700.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 500 Underlying: Common Stock · 2,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,180 Underlying: Common Stock · 10,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $71.00 | $142,000.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,532 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $39.87 | $79,740.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 7,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $71.00 | $710,000.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $39.87 | $398,700.00 |
DisclosureSEC source: 0000874015-19-000118 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000116 · edgar.xml · derivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,180 Underlying: Common Stock · 10,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $70.25 | $702,506.00 |
DisclosureSEC source: 0000874015-19-000116 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.25 to $70.26, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $39.87 | $398,700.00 |
DisclosureSEC source: 0000874015-19-000116 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 700 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 19 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,500 Underlying: Common Stock · 700 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 18 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,320 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 17 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,180 Underlying: Common Stock · 13,320 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,680 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 16 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,680 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 700 | $84.75 | $59,325.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 12 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,532 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 700 | $39.87 | $27,909.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 11 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 300 | $84.75 | $25,425.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,532 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 300 | $10.82 | $3,246.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 13,320 | $84.56 | $1,126,369.84 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.50 to $84.75, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 13,320 | $39.87 | $531,068.40 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,680 | $84.75 | $566,130.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,680 | $14.69 | $98,129.20 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 15 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 300 Underlying: Common Stock · 1,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 14 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,680 Underlying: Common Stock · 10,000 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $85.25 | $85,250.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,532 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.82 | $10,820.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $85.25 | $852,500.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $14.69 | $146,900.00 |
DisclosureSEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 Underlying: Common Stock · 37,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 37,000 | $61.54 | $2,276,798.70 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.45 to $61.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 37,000 | $39.87 | $1,475,190.00 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 40,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 40,000 | $60.07 | $2,402,700.00 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.02 to $60.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 40,000 | $39.87 | $1,594,800.00 |
DisclosureSEC source: 0000874015-19-000042 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000038 · edgar.xml · derivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,200 Underlying: Common Stock · 5,300 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,604 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000038 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 1,300 Underlying: Common Stock · 1,604 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000038 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 40,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,300 | $60.00 | $318,000.00 |
DisclosureSEC source: 0000874015-19-000038 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,532 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.